Study 329
Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating depressed teenagers. Marketed as Paxil and Seroxat (among other names), paroxetine had been released in 1991 by the British pharmaceutical company SmithKline Beecham, known since 2000 as GlaxoSmithKline (GSK). The drug made $11.6 billion between 1997 and 2006.
seeAlso
primaryTopic
Study 329
Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating depressed teenagers. Marketed as Paxil and Seroxat (among other names), paroxetine had been released in 1991 by the British pharmaceutical company SmithKline Beecham, known since 2000 as GlaxoSmithKline (GSK). The drug made $11.6 billion between 1997 and 2006.
has abstract
Study 329 was a clinical trial ...... more cardiovascular problems.
@en
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
46,602,356
Wikipage revision ID
723,124,285
Caption
Paroxetine, sold as Paxil and Seroxat
dates
funding
SmithKline Beecham, now GlaxoSmithKline
image size
lead researcher
Martin Keller, then professor of psychiatry and human behavior, Brown University
locations
name
protocol
published article
published year
study type
Eight-week, double-blind, rand ...... with major depressive disorder
hypernym
type
comment
Study 329 was a clinical trial ...... billion between 1997 and 2006.
@en
label
Study 329
@en
